跳至主要内容
临床试验/NCT00903721
NCT00903721已完成不适用

Nasonex® Nasal Suspension 50 μg Long-term Designated Drug Use Investigation

Organon and Co0 个研究点目标入组 3,806 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
3,806
主要终点
Estimate the incidence of Adverse Drug Reactions (ADRs)

研究概览

简要总结

The investigation will be conducted to define safety and efficacy under the conditions of post-marketing use of this drug in subjects with allergic rhinitis.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who are treated with Nasonex for perennial or seasonal allergic rhinitis.

排除标准

  • Patients with an infection for which there is no effective antimicrobial drug or systemic fungal infection [symptoms may exacerbate]
  • Patients with a history of hypersensitivity to any ingredient of this drug

研究组 & 干预措施

2

Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)

干预措施: mometasone furoate (Drug)

1

Patients with perennial allergic rhinitis

干预措施: mometasone furoate (Drug)

结局指标

主要结局

Estimate the incidence of Adverse Drug Reactions (ADRs)

时间窗: After 6 months of observation

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验